II. Indications
- Not typically used for Hypertension
- Diuretic Resistance in Edematous States
III. Dosing: Edema (CHF, renal disease)
- Take 30 minutes before Loop Diuretic
- Start: 2.5 mg daily (esp. if combined with Loop Diuretic)
- Target: 5 to 10 mg orally daily
- Maximum: 10 mg/day in CHF (20 mg/day in renal disease)
IV. Mechanism
V. Pharmacokinetics
- Onset of activity within 1 hour
- Duration >24 hours
VI. Adverse Effects
- See Thiazide Diuretic
- Monitor for Electrolyte disturbance (esp. when combined with Loop Diuretics)
- Hypovolemia with contraction alkalosis
- Hypokalemia
- Hyperuricemia
- Hyperglycemia
- Hyperlipidemia
- Hypercalcemia
VII. Safety
- Unknown Safety in Lactation
- Pregnancy Category B
- Pregnancy Category D if used for Pregnancy Induced Hypertension
VIII. Resources
IX. References
- (2021) Presc Lett, Resource #370507, Commonly Used Diuretics
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 62-3
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
metolazone (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
METOLAZONE 10 MG TABLET | Generic | $0.81 each |
METOLAZONE 2.5 MG TABLET | Generic | $0.52 each |
METOLAZONE 5 MG TABLET | Generic | $0.80 each |
Ontology: Metolazone (C0025854)
Definition (MSH) | A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS. |
Definition (NCI) | A long acting, quinazoline-based sulfonamide thiazide-like, diuretic. Similar to the thiazides, metolazone acts on the distal convoluted tubule (DCT) and inhibits the sodium-chloride symporter, thereby preventing sodium and chloride reabsorption and excretion of water. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D008788 |
SnomedCT | 22198003, 387123003 |
LNC | LP17954-6, MTHU003340 |
English | Metolazone, 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-, 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone, 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide, 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide, metolazone, metolazone (medication), METOLAZONE, Metolazone [Chemical/Ingredient], Metolazone (product), Metolazone (substance) |
Swedish | Metolazon |
Czech | metolazon |
Finnish | Metolatsoni |
Russian | METOLAZON, МЕТОЛАЗОН |
Japanese | メトラゾン |
Polish | Metolazon |
Spanish | metolazona (producto), metolazona (sustancia), metolazona, Metolazona |
French | Métolazone |
German | Metolazon |
Italian | Metolazone |
Portuguese | Metolazona |
Ontology: Zaroxolyn (C0701383)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D008788 |
English | zaroxolyn, UCB Pharma Brand of Metolazone, Zaroxolyn |